JP2022526524A - 喘息の処置のためのリポカリンムテイン - Google Patents

喘息の処置のためのリポカリンムテイン Download PDF

Info

Publication number
JP2022526524A
JP2022526524A JP2021557186A JP2021557186A JP2022526524A JP 2022526524 A JP2022526524 A JP 2022526524A JP 2021557186 A JP2021557186 A JP 2021557186A JP 2021557186 A JP2021557186 A JP 2021557186A JP 2022526524 A JP2022526524 A JP 2022526524A
Authority
JP
Japan
Prior art keywords
fragment
manifold
lipocalin mutane
lipocalin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526524A5 (https=
JPWO2020200960A5 (https=
Inventor
テルエス アクセルソン，レーナ
ロバート クローズ，デイビッド
ガーディナー，フィリップ
インゲルガルド アレクサンドラ ヤウヒアニネン，アウリッキ
パルダリ，エカテリーナ
フィッツジェラルド，メアリー
マッチナー，ガブリエーレ
ブルンス，インマル
マリータ オルソン，グンネル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2022526524A publication Critical patent/JP2022526524A/ja
Publication of JP2022526524A5 publication Critical patent/JP2022526524A5/ja
Publication of JPWO2020200960A5 publication Critical patent/JPWO2020200960A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Otolaryngology (AREA)
  • Cell Biology (AREA)
JP2021557186A 2019-03-29 2020-03-25 喘息の処置のためのリポカリンムテイン Pending JP2022526524A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962826791P 2019-03-29 2019-03-29
US62/826,791 2019-03-29
US201962845774P 2019-05-09 2019-05-09
US62/845,774 2019-05-09
US201962906443P 2019-09-26 2019-09-26
US62/906,443 2019-09-26
PCT/EP2020/058360 WO2020200960A1 (en) 2019-03-29 2020-03-25 Lipocalin mutein for treatment of asthma

Publications (3)

Publication Number Publication Date
JP2022526524A true JP2022526524A (ja) 2022-05-25
JP2022526524A5 JP2022526524A5 (https=) 2023-03-29
JPWO2020200960A5 JPWO2020200960A5 (https=) 2023-03-29

Family

ID=70008540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557186A Pending JP2022526524A (ja) 2019-03-29 2020-03-25 喘息の処置のためのリポカリンムテイン

Country Status (11)

Country Link
US (1) US20220193191A1 (https=)
EP (1) EP3946415A1 (https=)
JP (1) JP2022526524A (https=)
KR (1) KR20210146934A (https=)
CN (1) CN113613669A (https=)
AU (1) AU2020252050A1 (https=)
CA (1) CA3133422A1 (https=)
IL (1) IL286756A (https=)
MA (1) MA55490A (https=)
SG (1) SG11202109839YA (https=)
WO (1) WO2020200960A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020253034A1 (en) * 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
KR20230121785A (ko) 2020-12-18 2023-08-21 아스트라제네카 에이비이 천식 치료용 리포칼린 뮤테인 건조 분말 제형
WO2023143351A1 (zh) 2022-01-29 2023-08-03 上海盛迪医药有限公司 糖皮质激素的药物偶联物
CN114780621B (zh) * 2022-06-23 2022-10-04 中铁电气化勘测设计研究院有限公司 一种轨道交通接触网缺陷检索方法
WO2025026216A1 (zh) 2023-07-28 2025-02-06 江苏恒瑞医药股份有限公司 一种含有糖皮质激素的抗体药物偶联物的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537400A (ja) * 2010-06-08 2013-10-03 ピエリス アーゲー ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
JP2015505303A (ja) * 2011-12-13 2015-02-19 ピエリス アーゲー Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
US8313924B2 (en) 2006-08-01 2012-11-20 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537400A (ja) * 2010-06-08 2013-10-03 ピエリス アーゲー ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
JP2015505303A (ja) * 2011-12-13 2015-02-19 ピエリス アーゲー Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AM. J. RESPIR. CRIT. CARE MED., 2018, VOL. 197, NO. A1354, JPN6024006707, ISSN: 0005412327 *
THE DISCOVERY AND DEVELOPMENT OF AZD1402/PRS-060 A POTENT AND SELECTIVE BLOCKER OF IL-4 RECEPTOR ALP, JPN6024006706, ISSN: 0005412326 *

Also Published As

Publication number Publication date
EP3946415A1 (en) 2022-02-09
AU2020252050A1 (en) 2021-11-11
IL286756A (en) 2021-10-31
WO2020200960A1 (en) 2020-10-08
SG11202109839YA (en) 2021-10-28
CN113613669A (zh) 2021-11-05
US20220193191A1 (en) 2022-06-23
MA55490A (fr) 2022-02-09
KR20210146934A (ko) 2021-12-06
CA3133422A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
JP2022526524A (ja) 喘息の処置のためのリポカリンムテイン
US20250127712A1 (en) Compositions and methods for the treatment of opioid overdose
Gibson et al. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8
EP2627673B1 (en) Therapies for improving pulmonary function
Hodsman et al. A phase 1, randomized, placebo‐controlled, dose‐escalation study of an anti‐IL‐13 monoclonal antibody in healthy subjects and mild asthmatics
US8410049B2 (en) Methods and kits for preventing hypoglycemia
US20140378394A1 (en) Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
Tenero et al. Effect of montelukast on markers of airway remodeling in children with asthma.
US20240197719A1 (en) Formulations and methods for the prevention of opioid overdose
Phipps et al. Anti-IL-5 (mepolizumab) reduces the expression of tenascin, procollagen III and lumican in the reticular basement membrane of human atopic asthmatics
TW202241490A (zh) 用於治療氣喘之脂質運載蛋白突變蛋白乾粉配製物
KR20240033039A (ko) 호흡기 질환의 치료
WO2025124536A1 (zh) 趋化因子受体8拮抗多肽化合物、组合物、试剂盒及用途
Mason American Thoracic Society 2019 International Conference. Dallas, Texas, USA-May 17-22, 2019
Elsner et al. CRIC3, a chemokine receptor inactivator as a novel approach in the treatment of allergic diseases
US20100063251A1 (en) Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases
Petraitytė Utilization and costs of drugs for asthma and chronic obstructive pulmonary disease treatment in Lithuania on 2006-2009 year
HK1188603A (en) Therapies for improving pulmonary function
HK1188603B (en) Therapies for improving pulmonary function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230320

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240910